Compared with no study treatment ( n = 22 ) , rifaximin ( n = 43 ) use was associated with a significant difference between study arms in the change from baseline to week 4 for CD8 ( + ) T-cell activation ( median change , 0.0 % with rifaximin vs +0.6 % with no treatment ; P = .03 ) .